ASH 2024

This study presented a comparative analysis between low-dose and standard-dose Nivolumab regimens in the treatment of patients with relapsed or refractory Hodgkin Lymphoma. The presentation focused on evaluating the efficacy and clinical outcomes of these two distinct dosing approaches, providing a comparative look at how different concentrations impact patient disease progression and response rates.

The work contributed essential clinical evidence to the field of haematology, specifically regarding immunotherapy optimization. By comparing these dosing strategies, the presentation offered valuable insights into refining treatment protocols for patients facing relapsed or refractory Hodgkin Lymphoma, aimed at maximizing therapeutic efficacy while tailoring care to individual patient needs.

Upcoming Events